SONM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
DNA X Inc (SONM) is not a strong buy at the moment for a beginner investor with a long-term strategy. The lack of positive news, insider selling, and weak financial performance metrics outweigh the minor technical indicators and pre-market price stability. A hold is recommended until stronger positive catalysts emerge.
The MACD is positive at 0.0755 but contracting, RSI is neutral at 49.209, and moving averages are converging, indicating no clear trend. Key support is at 4.967, and resistance is at 6.954. Pre-market price is stable at 5.5, below the pivot of 5.96.
Net income improved significantly YoY, reducing losses by 89.21%.
Insiders are selling heavily, with a 610.08% increase in selling over the last month. Gross margin dropped significantly by 60.24% YoY. No recent news or external positive sentiment. Congress trading data shows no activity.
In Q3 2025, revenue increased to $16,214,000 (up 7.94% YoY), net income improved to -$4,753,000 (up 89.21% YoY), and EPS improved significantly to -86.86 (up 831.97% YoY). However, gross margin dropped sharply to 11.2%, a decrease of 60.24% YoY.
No analyst rating or price target changes available.
